Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Apr 15;99(8):1906–1916. doi: 10.1172/JCI119358

Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

R D Cohen 1, L W Castellani 1, J H Qiao 1, B J Van Lenten 1, A J Lusis 1, K Reue 1
PMCID: PMC508015  PMID: 9109435

Abstract

Transgenic mouse lines carrying several copies of the mouse apo A-IV gene were produced. Lipoprotein composition and function, and aortic lesion development were examined. Apo A-IV levels in the plasma of transgenic mice were elevated threefold compared with nontransgenic littermates on a chow diet, and sixfold in mice fed an atherogenic diet. Plasma concentrations of total cholesterol, HDL cholesterol, triglycerides, and free fatty acids were similar in transgenic and control mice fed a chow diet. However, with the atherogenic diet, male transgenic mice exhibited significantly higher levels of plasma triglycerides (P < 0.05), total cholesterol (P < 0.01), HDL cholesterol (P < 0.0001), and free fatty acids (P < 0.05), and lower levels of unesterified cholesterol (P < 0.05), than nontransgenic littermates. Expression of the apo A-IV transgene had a protective effect against the formation of diet-induced aortic lesions, with transgenics exhibiting lesion scores of approximately 30% those seen in control mice. HDL-sized lipoproteins isolated from transgenic mice fed the atherogenic diet promoted cholesterol efflux from cholesterol-loaded human monocytes more efficiently than comparable lipoproteins from nontransgenic counterparts. Plasma from transgenics also exhibited higher endogenous cholesterol esterification rates. Taken together, these results suggest that apo A-IV levels influence the metabolism and antiatherogenic properties of HDL.

Full Text

The Full Text of this article is available as a PDF (281.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalto-Setälä K., Bisgaier C. L., Ho A., Kieft K. A., Traber M. G., Kayden H. J., Ramakrishnan R., Walsh A., Essenburg A. D., Breslow J. L. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior. J Clin Invest. 1994 Apr;93(4):1776–1786. doi: 10.1172/JCI117163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berliner J. A., Navab M., Fogelman A. M., Frank J. S., Demer L. L., Edwards P. A., Watson A. D., Lusis A. J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995 May 1;91(9):2488–2496. doi: 10.1161/01.cir.91.9.2488. [DOI] [PubMed] [Google Scholar]
  3. Bernard D. W., Rodriguez A., Rothblat G. H., Glick J. M. Influence of high density lipoprotein on esterified cholesterol stores in macrophages and hepatoma cells. Arteriosclerosis. 1990 Jan-Feb;10(1):135–144. doi: 10.1161/01.atv.10.1.135. [DOI] [PubMed] [Google Scholar]
  4. Bisaha J. G., Simon T. C., Gordon J. I., Breslow J. L. Characterization of an enhancer element in the human apolipoprotein C-III gene that regulates human apolipoprotein A-I gene expression in the intestinal epithelium. J Biol Chem. 1995 Aug 25;270(34):19979–19988. doi: 10.1074/jbc.270.34.19979. [DOI] [PubMed] [Google Scholar]
  5. Bisgaier C. L., Sachdev O. P., Lee E. S., Williams K. J., Blum C. B., Glickman R. M. Effect of lecithin:cholesterol acyltransferase on distribution of apolipoprotein A-IV among lipoproteins of human plasma. J Lipid Res. 1987 Jun;28(6):693–703. [PubMed] [Google Scholar]
  6. Bisgaier C. L., Sachdev O. P., Megna L., Glickman R. M. Distribution of apolipoprotein A-IV in human plasma. J Lipid Res. 1985 Jan;26(1):11–25. [PubMed] [Google Scholar]
  7. Breslow J. L. Lipoprotein metabolism and atherosclerosis susceptibility in transgenic mice. Curr Opin Lipidol. 1994 Jun;5(3):175–184. doi: 10.1097/00041433-199405030-00004. [DOI] [PubMed] [Google Scholar]
  8. Buchberg A. M., Kinniburgh A. J. Induction of liver apolipoprotein A-IV mRNA in porphyric mice. Nucleic Acids Res. 1985 Mar 25;13(6):1953–1963. doi: 10.1093/nar/13.6.1953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen C. H., Albers J. J. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. Biochim Biophys Acta. 1985 Oct 2;836(3):279–285. doi: 10.1016/0005-2760(85)90131-6. [DOI] [PubMed] [Google Scholar]
  10. DeLamatre J. G., Hoffmeier C. A., Lacko A. G., Roheim P. S. Distribution of apolipoprotein A-IV between the lipoprotein and the lipoprotein-free fractions of rat plasma: possible role of lecithin:cholesterol acyltransferase. J Lipid Res. 1983 Dec;24(12):1578–1585. [PubMed] [Google Scholar]
  11. Duverger N., Ghalim N., Ailhaud G., Steinmetz A., Fruchart J. C., Castro G. Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb. 1993 Jan;13(1):126–132. doi: 10.1161/01.atv.13.1.126. [DOI] [PubMed] [Google Scholar]
  12. Duverger N., Ghalim N., Ailhaud G., Steinmetz A., Fruchart J. C., Castro G. Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb. 1993 Jan;13(1):126–132. doi: 10.1161/01.atv.13.1.126. [DOI] [PubMed] [Google Scholar]
  13. Duverger N., Tremp G., Caillaud J. M., Emmanuel F., Castro G., Fruchart J. C., Steinmetz A., Denèfle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996 Aug 16;273(5277):966–968. doi: 10.1126/science.273.5277.966. [DOI] [PubMed] [Google Scholar]
  14. Elshourbagy N. A., Boguski M. S., Liao W. S., Jefferson L. S., Gordon J. I., Taylor J. M. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8242–8246. doi: 10.1073/pnas.82.23.8242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fielding C. J., Fielding P. E. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3911–3914. doi: 10.1073/pnas.78.6.3911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Francone O. L., Gong E. L., Ng D. S., Fielding C. J., Rubin E. M. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. J Clin Invest. 1995 Sep;96(3):1440–1448. doi: 10.1172/JCI118180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fujimoto K., Cardelli J. A., Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol. 1992 Jun;262(6 Pt 1):G1002–G1006. doi: 10.1152/ajpgi.1992.262.6.G1002. [DOI] [PubMed] [Google Scholar]
  18. Fujimoto K., Fukagawa K., Sakata T., Tso P. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest. 1993 Apr;91(4):1830–1833. doi: 10.1172/JCI116395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ghiselli G., Krishnan S., Beigel Y., Gotto A. M., Jr Plasma metabolism of apolipoprotein A-IV in humans. J Lipid Res. 1986 Aug;27(8):813–827. [PubMed] [Google Scholar]
  20. Goldberg I. J., Scheraldi C. A., Yacoub L. K., Saxena U., Bisgaier C. L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem. 1990 Mar 15;265(8):4266–4272. [PubMed] [Google Scholar]
  21. Hedrick C. C., Castellani L. W., Warden C. H., Puppione D. L., Lusis A. J. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993 Sep 25;268(27):20676–20682. [PubMed] [Google Scholar]
  22. Ishida B. Y., Blanche P. J., Nichols A. V., Yashar M., Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res. 1991 Apr;32(4):559–568. [PubMed] [Google Scholar]
  23. Jiao S., Cole T. G., Kitchens R. T., Pfleger B., Schonfeld G. Genetic heterogeneity of plasma lipoproteins in the mouse: control of low density lipoprotein particle sizes by genetic factors. J Lipid Res. 1990 Mar;31(3):467–477. [PubMed] [Google Scholar]
  24. Lagrost L., Gambert P., Boquillon M., Lallemant C. Evidence for high density lipoproteins as the major apolipoprotein A-IV-containing fraction in normal human serum. J Lipid Res. 1989 Oct;30(10):1525–1534. [PubMed] [Google Scholar]
  25. Langner C. A., Birkenmeier E. H., Ben-Zeev O., Schotz M. C., Sweet H. O., Davisson M. T., Gordon J. I. The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. J Biol Chem. 1989 May 15;264(14):7994–8003. [PubMed] [Google Scholar]
  26. LeBoeuf R. C., Doolittle M. H., Montcalm A., Martin D. C., Reue K., Lusis A. J. Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. J Lipid Res. 1990 Jan;31(1):91–101. [PubMed] [Google Scholar]
  27. Lefevre M., Roheim P. S. Metabolism of apolipoprotein A-IV. J Lipid Res. 1984 Dec 15;25(13):1603–1610. [PubMed] [Google Scholar]
  28. Li H., Reddick R. L., Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993 Dec;13(12):1814–1821. doi: 10.1161/01.atv.13.12.1814. [DOI] [PubMed] [Google Scholar]
  29. Mackness M. I., Arrol S., Durrington P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991 Jul 29;286(1-2):152–154. doi: 10.1016/0014-5793(91)80962-3. [DOI] [PubMed] [Google Scholar]
  30. Mehlum A., Staels B., Duverger N., Tailleux A., Castro G., Fievet C., Luc G., Fruchart J. C., Olivecrona G., Skretting G. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem. 1995 Jun 1;230(2):567–575. doi: 10.1111/j.1432-1033.1995.tb20597.x. [DOI] [PubMed] [Google Scholar]
  31. Navab M., Hough G. P., Stevenson L. W., Drinkwater D. C., Laks H., Fogelman A. M. Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J Clin Invest. 1988 Dec;82(6):1853–1863. doi: 10.1172/JCI113802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ohta T., Nakamura R., Takata K., Saito Y., Yamashita S., Horiuchi S., Matsuda I. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res. 1995 Apr;36(4):696–704. [PubMed] [Google Scholar]
  33. Paigen B., Plump A. S., Rubin E. M. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol. 1994 Aug;5(4):258–264. doi: 10.1097/00041433-199408000-00003. [DOI] [PubMed] [Google Scholar]
  34. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992 Oct 16;71(2):343–353. doi: 10.1016/0092-8674(92)90362-g. [DOI] [PubMed] [Google Scholar]
  35. Qiao J. H., Xie P. Z., Fishbein M. C., Kreuzer J., Drake T. A., Demer L. L., Lusis A. J. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb. 1994 Sep;14(9):1480–1497. doi: 10.1161/01.atv.14.9.1480. [DOI] [PubMed] [Google Scholar]
  36. Reue K., Leete T. H. Genetic variation in mouse apolipoprotein A-IV due to insertion and deletion in a region of tandem repeats. J Biol Chem. 1991 Jul 5;266(19):12715–12721. [PubMed] [Google Scholar]
  37. Reue K., Purcell-Huynh D. A., Leete T. H., Doolittle M. H., Durstenfeld A., Lusis A. J. Genetic variation in mouse apolipoprotein A-IV expression is determined pre- and post-transcriptionally. J Lipid Res. 1993 Jun;34(6):893–903. [PubMed] [Google Scholar]
  38. Reue K., Rehnmark S. Screening transgenic mice by PCR: detection of tandem repeats. Biotechniques. 1994 Aug;17(2):252–253. [PubMed] [Google Scholar]
  39. Roheim P. S., Edelstein D., Pinter G. G. Apolipoproteins in rat serum and renal lymph. Proc Natl Acad Sci U S A. 1976 May;73(5):1757–1760. doi: 10.1073/pnas.73.5.1757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rubin E. M., Krauss R. M., Spangler E. A., Verstuyft J. G., Clift S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991 Sep 19;353(6341):265–267. doi: 10.1038/353265a0. [DOI] [PubMed] [Google Scholar]
  41. Schultz J. R., Gong E. L., McCall M. R., Nichols A. V., Clift S. M., Rubin E. M. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem. 1992 Oct 25;267(30):21630–21636. [PubMed] [Google Scholar]
  42. Schultz J. R., Rubin E. M. The properties of HDL in genetically engineered mice. Curr Opin Lipidol. 1994 Apr;5(2):126–137. doi: 10.1097/00041433-199404000-00009. [DOI] [PubMed] [Google Scholar]
  43. Schultz J. R., Verstuyft J. G., Gong E. L., Nichols A. V., Rubin E. M. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993 Oct 21;365(6448):762–764. doi: 10.1038/365762a0. [DOI] [PubMed] [Google Scholar]
  44. Sloop C. H., Dory L., Hamilton R., Krause B. R., Roheim P. S. Characterization of dog peripheral lymph lipoproteins: the presence of a disc-shaped "nascent" high density lipoprotein. J Lipid Res. 1983 Nov;24(11):1429–1440. [PubMed] [Google Scholar]
  45. Sloop C. H., Dory L., Roheim P. S. Interstitial fluid lipoproteins. J Lipid Res. 1987 Mar;28(3):225–237. [PubMed] [Google Scholar]
  46. Stampfer M. J., Sacks F. M., Salvini S., Willett W. C., Hennekens C. H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991 Aug 8;325(6):373–381. doi: 10.1056/NEJM199108083250601. [DOI] [PubMed] [Google Scholar]
  47. Stein O., Stein Y., Lefevre M., Roheim P. S. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta. 1986 Aug 14;878(1):7–13. doi: 10.1016/0005-2760(86)90337-1. [DOI] [PubMed] [Google Scholar]
  48. Steinmetz A., Barbaras R., Ghalim N., Clavey V., Fruchart J. C., Ailhaud G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem. 1990 May 15;265(14):7859–7863. [PubMed] [Google Scholar]
  49. Steinmetz A., Utermann G. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem. 1985 Feb 25;260(4):2258–2264. [PubMed] [Google Scholar]
  50. Utermann G., Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem. 1979 Sep;99(2):333–343. doi: 10.1111/j.1432-1033.1979.tb13261.x. [DOI] [PubMed] [Google Scholar]
  51. Van Lenten B. J., Hama S. Y., de Beer F. C., Stafforini D. M., McIntyre T. M., Prescott S. M., La Du B. N., Fogelman A. M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758–2767. doi: 10.1172/JCI118345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Vézina C. A., Milne R. W., Weech P. K., Marcel Y. L. Apolipoprotein distribution in human lipoproteins separated by polyacrylamide gradient gel electrophoresis. J Lipid Res. 1988 May;29(5):573–585. [PubMed] [Google Scholar]
  53. Walsh A., Azrolan N., Wang K., Marcigliano A., O'Connell A., Breslow J. L. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. J Lipid Res. 1993 Apr;34(4):617–623. [PubMed] [Google Scholar]
  54. Warden C. H., Hedrick C. C., Qiao J. H., Castellani L. W., Lusis A. J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993 Jul 23;261(5120):469–472. doi: 10.1126/science.8332912. [DOI] [PubMed] [Google Scholar]
  55. Watson A. D., Navab M., Hama S. Y., Sevanian A., Prescott S. M., Stafforini D. M., McIntyre T. M., Du B. N., Fogelman A. M., Berliner J. A. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Feb;95(2):774–782. doi: 10.1172/JCI117726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Weinberg R. B., Patton C. S. Binding of human apolipoprotein A-IV to human hepatocellular plasma membranes. Biochim Biophys Acta. 1990 May 22;1044(2):255–261. doi: 10.1016/0005-2760(90)90311-k. [DOI] [PubMed] [Google Scholar]
  57. Weinberg R. B., Spector M. S. Structural properties and lipid binding of human apolipoprotein A-IV. J Biol Chem. 1985 Apr 25;260(8):4914–4921. [PubMed] [Google Scholar]
  58. von Eckardstein A., Huang Y., Wu S., Sarmadi A. S., Schwarz S., Steinmetz A., Assmann G. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1755–1763. doi: 10.1161/01.atv.15.10.1755. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES